FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

EMSTER KURT VON 		2. Issuer Name and Ticker or Trading Symbol

Somaxon Pharmaceuticals, Inc. [ SOMX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O SOMAXON PHARMACEUTICALS, INC., 440 STEVENS AVENUE, SUITE 200 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/31/2012
(Street)

SOLANA BEACH, CA 92075
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/31/2012     A    6541   (1) A $0.00   27679   D    
Common Stock                  3214   I   By Trust  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Pursuant to the Director Compensation Policy, these RSUs were granted in lieu of cash board fees and retainers. Subject to the terms of the Restricted Stock Unit Agreement, 100% of the RSU Award shall vest upon the earlier of (a) the time that is immediately prior to the consummation of the merger contemplated by the Agreement and Plan of Merger by and among the Company, Pernix Therapeutics Holdings, Inc. and Pernix Acquisition Corp. I dated as of December 10, 2012 (the "Merger Agreement"), or (b) the first date included within an open trading window under the Company's Insider Trading Policy following any termination of the Merger Agreement, subject in either case to Participant's continued status as an Employee, Independent Director or Consultant (each as defined in the Plan) of the Company or any Subsidiary on such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
EMSTER KURT VON
C/O SOMAXON PHARMACEUTICALS, INC.
440 STEVENS AVENUE, SUITE 200
SOLANA BEACH, CA 92075 		X



Signatures
/s/ Matthew W. Onaitis, Attorney-in-fact 1/3/2013
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Somaxon (NASDAQ:SOMX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Somaxon Charts.
Somaxon (NASDAQ:SOMX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Somaxon Charts.